NEUROGENE INC. Share Price & Technical Analysis
NGNE · $23.25 (-2.92%)
Healthcare / Biotechnology
$23.25
-2.92%
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten diseas…
Price chart
Seasonality
Oct has 2 positive and 3 negative years (last 5 years shown)
-16% return in Oct, 30% avg return in past 3 year Oct month.
28% return in 2026, 71% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 34% | -14% | 29% | 9% | 12% | 3% | 8% | -22% | -16% | – | – | 28% |
| 25 | -32% | 16% | -34% | 27% | 13% | -14% | 41% | -13% | -6% | 98% | -32% | -1% | 63% |
| 24 | 56% | 5% | 63% | -32% | 10% | -4% | 13% | -9% | 13% | 6% | -43% | -9% | 68% |
| 23 | 21% | -17% | 35% | 30% | -11% | 2% | -14% | 11% | 4% | -15% | -5% | 41% | 83% |
| 22 | -27% | -28% | -28% | -35% | -17% | -2% | -2% | 2% | -39% | -16% | -9% | 2% | -198% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$466.47M
P/E ratio
—
52W high
$43.66
52W low
$15.93
Volume
5,71,499
Beta
2.09
Related stocks in Healthcare
Eli Lilly And Company
₹1,252
Mckesson Corporation
₹998.6
Frequently asked questions
- What is NEUROGENE INC. share price today?
- NEUROGENE INC. (NGNE) last traded around $23.25 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NGNE have?
- StockPro currently tracks 1 active signal(s) for NGNE, including breakouts, momentum, and volume patterns. See the signals panel on this page.
- How can I analyze NEUROGENE INC. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.